Spurred on by the Trump administration’s embrace of psychedelic medicine, researchers are experimenting with new — and not so new — forms of the anesthetic.

Cardiologists are struggling to figure out why a drug that should have prevented heart attacks didn’t work at all.

The first-of-its-kind drug offers a reprieve for people who live with the debilitating sleep disorder.

Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.

Artificial intelligence was used to help develop a drug candidate, rentosertib, for a rare lung condition. Its maker says the drug also seems to reduce the biological hallmarks of age.

Artificial intelligence was used to help develop a drug candidate, rentosertib, for a rare lung condition. Its maker says the drug also seems to reduce the biological hallmarks of age.

The drug targeted inflammation, and its shocking failure has experts questioning whether inflammation really does cause heart disease.

The agency had initially refused to even review the application but reversed course after a public outcry.

In an all-day hearing, the agency’s scientists argued against allowing broad access to unproven drugs that the agency had banned three years ago.

A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline.

Trials are beginning on several drugs that have shown promise in preliminary studies against the virus that is causing the current outbreak.

The Bundibugyo virus, a little known type, previously had caused just two small outbreaks. Now it’s at the center of a rapidly widening epidemic in Africa.

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.